A new injection reportedly cut the most dangerous belly fat by 12% in early human trials, measured by MRI.
Story Highlights
- Early trials of CBL-514 showed a 12% average drop in visceral fat by MRI, versus a 6% rise on placebo.
- Participants received lower-abdominal injections every three weeks for up to 12 weeks.
- A peer-reviewed Phase 2 study found significant loss of subcutaneous abdominal fat with CBL-514.
- Clinical registry entries describe randomized, placebo-controlled designs with over 180 combined enrollees.
What The New Trial Result Claims
Fox News reported that early human trials found a 12.01% average reduction in visceral fat after CBL-514 treatment, measured by magnetic resonance imaging four weeks after the final injection, while the placebo group saw a 5.68% increase. The study protocol involved injections to the lower abdomen every three weeks for up to 12 weeks, with doses up to 600 milligrams. Visceral fat is the fat around organs, which doctors link to higher risks for diabetes and heart disease.
Research registries show CBL-514 has been tested in randomized, single-blind, placebo-controlled Phase 2 studies. One registry lists 75 participants, and another lists 107 participants, supporting that the drug is being compared to placebo in organized trials. The reported magnetic resonance imaging result adds weight because it measures fat volume directly, not only scale weight. That matters since scale weight can hide shifts between fat and muscle.
What Is Already Peer-Reviewed
A 2025 Phase 2 paper reported that CBL-514 reduced abdominal subcutaneous fat in the treated area compared to placebo, with large between-group differences that were statistically significant at four and eight weeks. That study strengthens the idea that the drug can shrink local fat where injected. Subcutaneous fat sits under the skin, which is different from visceral fat around the organs. The peer-reviewed data focus on subcutaneous fat loss over the treatment sites.
The magnetic resonance imaging claim about visceral fat comes through media reporting rather than the same peer-reviewed paper. The report does not provide the visceral-fat sample size or a confidence interval. That limits how precisely people outside the study can judge the strength of the visceral-fat number. Still, a double-digit percentage change measured by magnetic resonance imaging is notable and will push interest in larger, longer studies.
Why Visceral Fat Matters For Health
Doctors watch visceral fat because it tracks with insulin resistance and heart risk. Prior lifestyle trials linked sizable visceral-fat drops to better metabolic scores years later, suggesting that targeting this fat can help health over time. That background does not prove that any single drug will copy those benefits. It does show that a measured visceral-fat drop can be meaningful if it holds up and lasts long enough. That is why the magnetic resonance imaging endpoint draws attention.
Government and medical groups also warn that cosmetic body contouring alone does not treat obesity or improve health by itself. Changes to deep fat may help, but they need proof of lasting gains in real outcomes like blood sugar and heart risk. That is the bar for drugs that claim health benefits beyond appearance. Magnetic resonance imaging can start the story, but long-term clinical data must finish it.
What Comes Next And What To Watch
Future studies can answer key questions that people across the spectrum care about. Trials should track insulin resistance, fasting insulin, and glucose tolerance, and link those results to each person’s magnetic resonance imaging changes. Researchers should also follow people for at least six to twelve months to see if visceral-fat loss lasts or rebounds. Clear reports with protocol numbers, analysis plans, and confidence intervals would help doctors and patients trust the results.
New injection CBL-514 shown to reduce visceral fat in human trialshttps://t.co/XjXKfFoDwz
— Ahsan Ali (@imsn_official) October 11, 2026
The sponsor, Caliway Biopharmaceuticals, is tied to the listed trials, so full and transparent reporting matters for credibility. For now, the concrete facts are these: an early human program used randomized, placebo-controlled designs; a peer-reviewed paper shows subcutaneous fat loss at injection sites; and media report a 12% average visceral-fat reduction by magnetic resonance imaging at four weeks after treatment. Larger, longer, and fully published results will show whether this moves from cosmetic change to real health benefit.
Sources:
clinicaltrials.gov, academic.oup.com, cdn.clinicaltrials.gov, fda.gov
© truetrendnews.com 2026. All rights reserved.
